Results 81 to 90 of about 22,886 (216)

Late diagnosis of HIV among Ukrainian refugees in the Czech Republic: A retrospective, observational study

HIV Medicine, Volume 26, Issue 6, Page 888-898, June 2025.
Abstract Objectives This retrospective, observational, non‐interventional study describes the demographics, characteristics, immunological and virological status, coinfections, healthcare unit of HIV diagnosis and follow‐up status of Ukrainian refugees with newly diagnosed HIV in the Czech Republic, with a special focus on those with a late HIV ...
Zofia Bartovská, Ricardo Massmann, David Jilich, Tomáš Groh, Lukáš Fleischhans, Milan Zlámal, Radek Svačinka, David Vydrář, Dalibor Sedláček, Miroslav Kubiska, Jaroslav Kapla, Lucie Nepovímová, Daniela Bartková, Lenka Olbrechtová, Zdeňka Jerhotová, Eva Novotná, Jakub Wnuk, Vratislav Němeček, Pavel Dlouhý, Štěpán Cimrman, Marek Malý   +20 more
wiley   +1 more source

Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors

European Journal of Medicinal Chemistry Reports
Acquired immune deficiency syndrome (AIDS) diseases despite the efficacy of anti-HIV therapy, remain one of the human's most serious problems. Hence, the introduction of novel anti-HIV agents as first-line therapy is still required. HIV integrase lacking
Nafiseh Karimi, Amirreza Dowlati Beirami, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi, Afshin Zarghi   +4 more
doaj  

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

Viruses
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase.
Irene Wanjiru Kiarie, Gyula Hoffka, Manon Laporte, Pieter Leyssen, Johan Neyts, József Tőzsér, Mohamed Mahdi   +6 more
doaj   +1 more source

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. [PDF]

Retrovirology, 2022
Zhao AV, Crutchley RD, Guduru RC, Ton K, Lam T, Min AC.   +5 more
europepmc   +1 more source

Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort

HIV Medicine, Volume 26, Issue 6, Page 970-977, June 2025.
Abstract Objectives Most treatment switches are for simplification from three‐drug (3DR) to dual regimens (2DR). However, a proportion of people with HIV may switch back to 3DR, like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after 2DR.
Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi‐Lepri, Andrea Giacomelli, Roberto Rossotti, Giacomo Ponta, Nicoletta Bobbio, Alice Ianniello, Antonella Cingolani, Giordano Madeddu, Andrea Antinori, Antonella d'Arminio Monforte, on behalf of ICONA Foundation Study Group, A. d'Arminio Monforte, A. Antinori, S. Antinori, A. Castagna, R. Cauda, G. Di Perri, E. Girardi, R. Iardino, A. Lazzarin, G. C. Marchetti, C. Mussini, E. Quiros‐Roldan, L. Sarmati, B. Suligoi, F. Von Schloesser, P. Viale, A. d'Arminio Monforte, A. Antinori, A. Castagna, F. Ceccherini‐Silberstein, A. Cingolani, A. Cozzi‐Lepri, A. Di Biagio, E. Girardi, A. Gori, S. Lo Caputo, G. Marchetti, F. Maggiolo, C. Mussini, M. Puoti, C. F. Perno, C. Torti, A. Antinori, A. Bandera, S. Bonora, A. Calcagno, D. Canetti, A. Castagna, F. Ceccherini‐Silberstein, A. Cervo, A. Cingolani, P. Cinque, A. Cozzi‐Lepri, A. d'Arminio Monforte, A. Di Biagio, R. Gagliardini, A. Giacomelli, E. Girardi, N. Gianotti, A. Gori, G. Guaraldi, S. Lanini, G. Lapadula, M. Lichtner, A. Lai, S. Lo Caputo, G. Madeddu, F. Maggiolo, V. Malagnino, G. Marchetti, A. Mondi, V. Mazzotta, C. Mussini, S. Nozza, C. F. Perno, S. Piconi, C. Pinnetti, M. Puoti, E. Quiros Roldan, R. Rossotti, S. Rusconi, M. M. Santoro, A. Saracino, L. Sarmati, V. Spagnuolo, N. Squillace, V. Svicher, L. Taramasso, C. Torti, A. Vergori, A. Cozzi‐Lepri, S. De Benedittis, I. Fanti, M. Giotta, C. Marelli, A. Rodano, A. Tavelli, M. Cernuschi, L. Cosmaro, A. Perziano, V. Calvino, D. Russo, M. Farinella, N. Policek, V. L. Del Negro, M. Augello, S. Carrara, S. Graziano, G. Prota, S. Truffa, D. Vincenti, R. Rovito, M. Sgarlata, I. A Giacometti, A. Costantini, V. Barocci, A. Saracino, C. Santoro, E. Milano, L. Comi, C. Suardi, P. Viale, L. Badia, S. Cretella, E. M. Erne, A. Pieri, E. Quiros Roldan, E. Focà, B. Menzaghi, C. Abeli, L. Chessa, F. Pes, P. Maggi, L. Alessio, G. Nunnari, B. M. Celesia, J. Vecchiet, K. Falasca, A. Pan, S. Dal Zoppo, D. Segala, F. Bartalesi, C. Costa, S. Lo Caputo, S. Ferrara, M. Bassetti, E. Pontali, S. Blanchi, N. Bobbio, C. Del Borgo, R. Marocco, G. Mancarella, S. Piconi, C. Molteni, S. Rusconi, G. Canavesi, G. Pellicanò, G. Marchetti, S. Antinori, G. Rizzardini, M. Puoti, A. Castagna, A. Bandera, V. Bono, M. V. Cossu, A. Giacomelli, R. Lolatto, M. C. Moioli, L. Pezzati, S. Diotallevi, C. Tincati, C. Mussini, M. Menozzi, P. Bonfanti, G. Lapadula, V. Sangiovanni, I. Gentile, V. Esposito, N. Coppola, F. M. Fusco, G. Di Filippo, V. Rizzo, N. Sangiovanni, S. Martini, A. M. Cattelan, D. Leoni, A. Cascio, M. Trizzino, D. Francisci, E. Schiaroli, G. Parruti, F. Sozio, D. Messeri, S. I. Bonelli, C. Lazzaretti, R. Corsini, A. Antinori, R. Cauda, C. Mastroianni, L. Sarmati, A. Latini, A. Cingolani, I. Mastrorosa, S. Lamonica, M. Capozzi, M. Camici, I. Mezzaroma, M. Rivano Capparuccia, G. Iaiani, C. Stingone, L. Gianserra, J. Paulicelli, M. M. Plazzi, G. d'Ettore, M. Fusto, M. Lichtner, I. Coledan, G. Madeddu, A. De Vito, M. Fabbiani, F. Montagnani, A. Franco, R. Fontana Del Vecchio, D. Francisci, C. Di Giuli, G. C. Orofino, G. Calleri, G. Di Perri, S. Bonora, G. Accardo, C. Tascini, A. Londero, G. Battagin, S. Nicolè, G. Starnini, S. Dell'Isola   +238 more
wiley   +1 more source

First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. [PDF]

Biochem Biophys Rep, 2022
Ghasabi F, Hashempour A, Khodadad N, Bemani S, Keshani P, Shekiba MJ, Hasanshahi Z.   +6 more
europepmc   +1 more source

Lipid abnormality correction by integrase inhibitor among children taking ARt

Журнал инфектологии, 2019
Goal. To estimate a possibility of correction laboratory abnormalities (increased level of cholesterol and/or triglycerides at blood of HIV-positive children) by switch the boosted PI on HIV integrase inhibitor (Raltegravir). Methods.
A. V. Samarina, N. S. Dyldina, E. K. Fertikh, E. B. Yastrebova, I. A. Abramova, D. A. Gusev   +5 more
doaj   +1 more source

The crystal structure of the catalytic core domain of HIV-1 integrase in a new crystal form [PDF]

, 1996
Fred Dyda, Alison B. Hickman, T.M. Jenkins, Alan Engelman, Robert Craigie, D.R. Davies   +5 more
openalex   +1 more source

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

Viruses, 2014
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source

A New Class of HIV-1 Integrase Inhibitors: The 3,3,3‘,3‘-Tetramethyl-1,1‘-spirobi(indan)-5,5‘,6,6‘-tetrol Family [PDF]

, 2000
Valentina Molteni, Denise Rhodes, Kathleen Rubins, Mark Hansen, Frederic D. Bushman, Jay S. Siegel   +5 more
openalex   +1 more source